

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

International Patent Classification 6 : A61K 49/00, 51/00	A1	(11) International Publication Number: WO-96/14091
		(43) International Publication Date: 17 May 1996 (17.05.96)
International Application Number: PCT/SE95/01212		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
International Filing Date: 17 October 1995 (17.10.95)		
Priority Data: 9403755-3 2 November 1994 (02.11.94) SE		
Applicant (<i>for all designated States except US</i>): DIABACT AB [SE/SE]; Holmvägen 22, S-756 61 Uppsala (SE).		
Inventors; and Inventors/Applicants (<i>for US only</i>): NYSTRÖM, Christer [SE/SE]; Holmvägen 22 B, S-756 61 Uppsala (SE). LUNDQVIST, Thomas [SE/SE]; Flogstavägen 146, S-752 63 Uppsala (SE). PETTERSSON, Anders [SE/SE]; Knäverstad 13060, S-442 97 Kode (SE).		
Agents: ONN, Thorsten et al.; AB Stockholms Patentbyrå, Zacco & Bruhn, P.O. Box 23101, S-104 35 Stockholm (SE).		

Published

*With international search report.
With amended claims.
In English translation (filed in Swedish).*

Title: DIAGNOSTIC PREPARATION FOR DETECTION OF HELICOBACTER PYLORI

Abstract

The present invention relates to a preparation for administering isotope-labelled urea together with acid in tablet form, in the form of capsule preparation, or in some other solid form. The preparation dissolves very quickly in the stomach. The preparation is used to show eased urease activity in the stomach in association with an ongoing Helicobacter pylori infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Montenegro
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Diagnostic preparation for detection of
Helicobacter Pylori

Diseases relating to gastric ulcers, are a serious public health problem and cost the community large sums of money in the form of medical costs and lost working ability.

5 It has been fully established that the presence of *Helicobacter pylori* in the stomach is a necessary prerequisite for the development of stomach ulcers and/or duodenal ulcers. If the bacterium is not present in the stomach, no ulcer will develop. It has also been established that when a *Helicobacter pylori* infection is cured with the aid of antibiotics, there will be no relapse in stomach ulcer diseases. Stomach ulcer diseases are therefore 10 considered to be bacterium-caused diseases which can and shall be cured.

There is a great need for a reliable and simple diagnosis in this regard, as large patient populations inflicted with gastrointestinal problems will need to be examined with regard to the presence of a *Helicobacter pylori* infection.

15 The present invention is based on the observation that the bacterium *Helicobacter pylori* produces the enzyme urease in very large quantities. The enzyme urease is normally not found in human beings, and its presence in the stomach indicates that *Helicobacter pylori* is present. *Helicobacter pylori* has established an ecological niche in the human 20 stomach. The bacterium thrives in a neutral pH, which is found beneath the mucus layer in the stomach. The bacterium produces large quantities of the enzyme urease, which in turn catalyzes the degradation of urea to ammonia and bicarbonate. The bicarbonate is then converted in the acid environment of the stomach to carbon dioxide and water.

25 In Sweden, about 470,000 patients seek medical care for stomach ulcer-like problems each year. The possibility of being able to diagnose and to treat *Helicobacter pylori* infections in a reliable and simple manner is therefore of great interest to the patient and also from the aspect of health economy.

30 The present invention pertains to a solid preparation for simple and reliable diagnosis

of ongoing urease activity in the stomach in conjunction with *Helicobacter pylori* infection.

Present-day methods of showing the presence of *Helicobacter pylori*

5

Biopsy methods

A common feature of these methods (cultivation of the bacterium, histological examination, quick urease test) is that they are carried out on biopsy material. This
10 means that the patient must undergo a gastroscopic examination of the stomach with the use of fibre optics, during which tissue samples are taken from the stomach epithelium. This examination is both expensive and unpleasant to the patient.

Serological methods

15

A common feature of these methods consists of determining the presence of specific antibodies against *Helicobacter pylori* in the blood or in stomach secretion. One drawback with these methods is that it is necessary to take blood samples or secretion from the stomach. Neither are serological methods able to show the presence of
20 bacteria on the occasion of making the examination.

It takes about twenty days from the time of being infected with *Helicobacter pylori* to the time that antibodies against the bacterium manifest themselves.

25 After successful treatment of the bacterial infection, elevated contents of antibodies remain in the blood for a very long time, thereby greatly limiting the possibility of accurately checking the condition of treated patients.

Urea-breath tests

30

The method is based on the production of the enzyme urease by the bacterium

Helicobacter pylori. Urease catalyzes the degradation of urea to ammonia and bicarbonate. The bicarbonate is then converted to carbon dioxide and water in the acid environment of the stomach.

- 5 At present, the urea-breath test is performed in the following manner: The patient swallows an aqueous solution containing isotope-labelled (^{11}C , ^{13}C , ^{14}C) urea. In the presence of urease-producing *Helicobacter pylori* and acid in the stomach, urea is broken down so that the isotope-labelled carbon atoms convert to carbon dioxide and are secreted via the exhaled air. The amount of isotope-labelled carbon dioxide in the
10 exhaled air is determined.

The advantages of this method are that the examination is non-invasive, i.e. the patient need not be subjected to instrumentation (gastroscopy) and neither need blood samples be taken or samples of secretion taken from the stomach. Furthermore, because the
15 urea supplied to the patient disperses over the whole surface of the stomach, the fact that the bacterium has a very spotty distribution area lacks significance.

The urea-breath test is disadvantageous on three separate counts:

- 20 1. Isotope-labelled urea is ingested as an aqueous solution. This means that the urea can be broken down by urease-producing bacteria in the oral cavity and the pharynx of the patient, which may result in falsely positive indications regarding the presence of *Helicobacter pylori*.
- 25 2. In order for the test to be successful, it is necessary for a given quantity of hydrogen ions to be present in the stomach in order for the bicarbonate formed to be converted into carbon dioxide. Many patients who suffer from stomach ulcers are treated with an acid-suppression inhibitors which gives a falsely negative test result when such patients are diagnosed in accordance with present methodology.
- 30 3. Isotope-labelled urea has only a short chemical durability in aqueous solution, which

causes practical difficulties when the patient is tested clinically..

It will be evident from the foregoing that several diagnostic methods of showing the presence of *Helicobacter pylori* in the stomach are known to the art, but that these 5 methods are encumbered with a number of disadvantages, for instance are deficient in positively showing the presence of bacteria or are unpleasant for the patient.

There is thus a need to improve such diagnostic methods so that a more reliable diagnosis can be made under all conditions, and to enhance the practical use of such 10 methods.

General disclosure of the invention

By constructing a capsule, tablet or some other solid preparation that has a high rate 15 of disintegration and contains isotope-labelled (¹¹C, ¹³C, ¹⁴C) urea in combination with an acid, the following four important advantages are obtained with urea-breath tests relating to the diagnosis of gastric ulcer diseases:

1. When isotope-labelled urea is administered in the form of a solid preparation, the 20 degradation by urease-producing bacteria in the oral cavity and the pharynx before the urea has reached the stomach is prevented. This reduces the number of falsely positive results and therewith significantly increases the reliability of the examination.

2. The administration of a weak acid at the same time as the isotope-labelled urea is 25 administered also enables the urea-breath test to be performed during ongoing acid-suppression inhibiting treatment. This is a significant gain, since the majority of the patients who are subjected to the urea-breath test are chronically treated with potent acid-secretion inhibiting drugs. This substantially reduces the occurrence of falsely negative results.

30

3. Because isotope-labelled urea and a weak acid in capsule, tablet or other solid form,

are stable over a relatively long period of time, the problems caused by the limited chemical stability of urea in aqueous solution are avoided.

5 This affords significant practical advantages with regard to distribution and application of the urea-breath test.

10 4. The use of a ready-prepared solid preparation (e.g. a tablet) also affords advantages with regard to dosage accuracy and time saving, in comparison with preparing the established water-based test liquid.

15 In order to be able to achieve these significant advantages, it is necessary to construct the solid preparation such that it affords protection of its contents from the influence of urease in the oral cavity and in the pharynx, and also such that it will break down rapidly and completely in the stomach.

15 Technical description of the invention

20 There is provided in accordance with the invention an essentially water-free preparation which contains primarily either ¹¹C, ¹³C or ¹⁴C labelled urea and an acid, for instance ascorbic acid, citric acid, tartaric acid or aciglumin, in a solid preparation intended for peroral administration to human beings. However, it should be noted that the invention is not restricted solely to urea and that the present invention also includes other substances or substrates that are influenced by the activity of *Helicobacter pylori* and that can be readily analyzed.

25 The preparation shall contain sufficient acid to produce a sufficiently low pH-value in the stomach when ingested. In this regard, a suitable pH value is beneath pH = 4. The amount of a specific acid required to obtain a desired pH in the stomach of a patient can be determined easily by the skilled person on the basis of simple routine tests.

30 The pharmaceutical preparation according to the invention is composed such that

isotope-labelled urea and acid will be released essentially immediately when the preparation reaches the stomach. A preferred form of the preparation includes ^{13}C urea and water-free citric acid. The preparation may either be a conventional tablet, optionally provided with a quickly soluble coating, although it may alternatively have the form of a capsule preparation. In this latter case, so-called hard gelatin capsules (operculate capsules) are intended, although soft gelatin capsules may also be used. The sole prerequisite is that the chemical stability is sufficiently high and that the active substance content of the preparation can be quickly released and dissolved. The chemical stability is normally improved when the active substances and auxiliary substances are present in solid form. The chemical stability will normally be sufficiently high when an oil solution is used in combination with a soft gelatin capsule.

Other solid preparations may also be used. Without limiting the list of those preparations that can be used in this regard, it can be mentioned that such preparations may include solid solutions, solid dispersions and so-called pellet preparations. By pellet preparations is meant larger or smaller grains produced by granulation or by extrusion/spheronization. The active substance can then be incorporated in these pellets or attached to their surfaces. The active pellets can then be compressed to a quickly disintegrating tablet form, or can be filled in hard gelatin capsules.

Tablets, which are the preferred form, can be produced with the aid of auxiliary substances and process steps well known to the skilled person. Thus, in order to obtain maximum rapid release and dissolution there are preferably used essentially water-soluble components and auxiliary substances which accelerate disintegration of the tablet. The auxiliary substances used may have the form of pharmaceutical bursting or disintegrating agents of a kind known to the skilled person. Particularly suitable agents in this regard are those which swell markedly in water by hydration, to a volume that corresponds to 10-20 times their dry volume. Examples of such agents include cellulose derivatives and starch derivatives in the form of cross-linked polymers which are insoluble in water but which swell markedly therein. Derivatives of polyvinyl pyrrolidone is another example of such agents. A modified cellulose-gum of high water

swellability and marketed under the trade name Ac-Di-Sol® by FMC Corporation, U.S.A., is a specific example of a suitable pharmaceutical disintegrating agent. Other types of pharmaceutical disintegrating agents may also be used, and the skilled person will have no problem in choosing a suitable agent.

5

In the case of a particularly preferred form, the active substance urea has a very fine particulate quality. In this form, the particle size is preferably smaller than 200 µm, and more preferably smaller than 20 µm. However, this does not exclude the use of particulate active substances of larger particle size, when the remainder of the 10 formulation so permits. Such assessments are well known to the skilled person.

10

Example

Tablets were prepared in accordance with the following for the purpose of testing the invention and comparing the invention with conventional techniques (aqueous solution):

5 The ingredients of the following composition were mixed in a conventional double-cone rotary mixer. Tablets were then compacted in a so-called excenter press machine having 12 mm concave-faced punches.

10 Composition of 1 tablet

- | | |
|---------------------------|-------|
| 1. Urea, ¹³ C | 50 mg |
| 2. Citric acid, anhydrous | 63 mg |
| 3. Avicel® Ph 101 | 60 mg |
| 15 4. Ac-Di-Sol® | 24 mg |
| 5. Magnesium stearate | 3 mg |

Avicel® Ph 101 is the trade name of a microcrystalline cellulose marketed by FMC Corporation, U.S.A.

20 Ac-Di-Sol® is the trade name of a modified cellulose gum of high swellability in water from FMC Corporation, U.S.A. In this case, it functions as a pharmaceutical disintegrating agent for a quick disintegration of the tablet.

25 In tests carried out on patients, either two tablets (corresponding to 100 mg urea) or 2.5 ml aqueous solution which also contained 100 mg urea were ingested by respective patients.

30 When making a comparison between isotope-labelled urea administered in accordance with a conventional technique (aqueous solution) and a preparation in accordance with the invention, isotope-labelled carbon dioxide was observed in the exhalation air of

eight patients who lacked the bacterium in the stomach, after ten minutes from the time of ingesting the aqueous solution.

When isotope-labelled urea was ingested in the form of a preparation according to the
5 invention, no isotope-labelled carbon dioxide was observed in the exhalation air of these patients.

When making a comparison between isotope-labelled urea in aqueous solution and isotope-labelled urea in solid preparation in accordance with the invention with ten
10 patients known to have stomach bacteria, markedly elevated quantities of isotope-labelled carbon dioxide were observed in the exhalation air ten minutes after having taken the tablet. When the isotope-labelled urea was taken in aqueous solution, it was necessary to wait a further ten minutes before it could be said positively that the
15 quantities of isotope-labelled carbon dioxide measured originated from urease in the stomach.

All of the aforesaid ten patients were treated with acid suppression medicine for a period of one week. Conventional urea-breath tests using isotope-labelled urea in aqueous solution showed a negative result in all cases.

20 When using isotope-labelled urea in solid preparation with an acid addition in accordance with the invention, the urease activity in the stomach of all ten patients was established.

10

Table 1: A compilation of the results obtained when diagnosing *Helicobacter pylori* with the aid of isotope-labelled urea in aqueous solution and in a solid preparation constructed in accordance with the invention.

5	Method	Falsely positive		Falsely negative		Number of patients tested
		10 min.	20 min.	10 min.	20 min.	
	Solution	8	0	-	-	18
	Tablet	0	0	-	-	18
10	Solution + treatment with acid-secretion inhibitor	-	-	10	10	10
	Tablet + treat- ment with acid- secretion in- hibitor	-	-	0	0	10

CLAIMS

1. A pharmaceutical preparation for detecting the presence of urease activity in the stomach in association with an *Helicobacter pylori* infection, characterized in that the preparation comprises a substance which is influenced by the activity of *Helicobacter pylori* to form an observable reaction product.

5 2. A preparation according to Claim 1, characterized in that it consists of a solid, essentially water-free composition which comprises isotope-labelled urea and a solid
10 water-soluble acid.

15 3. A preparation according to Claim 2, characterized in that the isotope-labelled urea is labelled with ¹¹C, ¹³C and/or ¹⁴C.

4. A preparation according to Claim 2 or Claim 3, characterized in that the acid is one or more of the acids ascorbic acid, tartaric acid, citric acid and aciglumin.

15 5. A preparation according to any one of Claims 2-4, characterized in that the acid is present in an amount which will generate a pH of below 4 in the stomach.

20 6. A preparation according to any one of Claims 2-5, characterized in that the preparation is composed for rapid release in the stomach after being administered.

15 7. A preparation according to any one of Claims 2-6, characterized in that the isotope-labelled urea has a particle size substantially smaller than 200 µm, and then preferably smaller than 20 µm.

12

AMENDED CLAIMS

[received by the International Bureau on 18 March 1996 (18.03.96);
original claims 1-7 replaced by amended claims 1-7 (1 page)]

1. A pharmaceutical preparation for detecting the presence of urease activity in the stomach in association with an infection by *Helicobacter pylori*, characterized in that said preparation consists of a solid, essentially water-free composition which comprises isotope-labelled urea, which is influenced by the activity of *Helicobacter pylori* to form a detectable reaction product, which accompanies exhaled air and is analyzed therein.
2. A preparation according to claim 1, characterized in that it comprises a solid, water-soluble acid.
3. A preparation according to claim 1 or 2, characterized in that the isotope-labelled urea is labelled with ^{11}C , ^{13}C and/or ^{14}C .
4. A preparation according to claim 2 or 3, characterized in that the acid is one or more of the acids ascorbic acid, tauric acid, citric acid and aciglumin.
5. A preparation according to any one of claims 2-4, characterized in that the acid is present in an amount which will generate a pH of below 4 in the stomach.
6. A preparation according to any one of claims 2-5, characterized in that it is formulated for a rapid dissolution in the stomach after having been administered.
7. A preparation according to any one of claims 2-6, characterized in that the isotope-labelled urea has a particle size essentially below 200 μm , and preferably then below 20 μm .

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 95/01212

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 49/00, A61K 51/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 9511672 A1 (MARSHALL, BARRY), 4 May 1995 (04.05.95) --	1-3
X	DD 294634 A5 (AKADEMIE DER WISSENSCHAFTEN), 10 October 1991 (10.10.91) --	1
X	Dialog Information services, MEDLINE accession no. 93220316, Lotterer E et al: "The 13C- urea breath test--detection of Helicobacter pylori infection in patients with partial gastrectomy"; & Z Gastroenterol, (1993 Feb) 31 (2) 115-9 -- -----	1

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

07 -02- 1996

29 January 1996

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Solveig Gustavsson
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

05/01/96

International application No.

PCT/SE 95/01212

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9511672	04/05/95	NONE	
DD-A5- 294634	10/10/91	NONE	